19617-90-4

Basic information

• Product Name: 1,2,4,5-tetrazine-3,6-diamine
• Synonyms: 1,2,4,5-Tetrazine-3,6-diamine
• CAS NO: 19617-90-4
• Molecular Formula: C₂H₄N₆
• Molecular Weight: 112.0934
• Mol File: 19617-90-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 459.2°C at 760 mmHg
• Flash Point: 262.3°C
• Density: 1.675g/cm³
• Vapor Pressure: 1.29E-08mmHg at 25°C
• Refractive Index: 1.744
• CAS DataBase Reference: 1,2,4,5-tetrazine-3,6-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4,5-tetrazine-3,6-diamine(19617-90-4)
• EPA Substance Registry System: 1,2,4,5-tetrazine-3,6-diamine(19617-90-4)

Safety Data

• Hazardous Substances Data: 19617-90-4(Hazardous Substances Data)

Usage

General Description

1,2,4,5-Tetrazine-3,6-diamine is a chemical compound that belongs to the tetrazine family. It is a yellow solid with the chemical formula C2H4N6 and is often used in organic synthesis and in the preparation of heterocyclic compounds. 1,2,4,5-Tetrazine-3,6-diamine has potential applications in the fields of pharmaceuticals, agrochemicals, and materials science due to its unique structural and chemical properties. It has been studied for its potential use in explosive materials, as well as in the development of novel dyes and polymers. Additionally, 1,2,4,5-Tetrazine-3,6-diamine has been investigated for its potential as a building block in the synthesis of complex organic molecules and may have future applications in various industries.

Upstream product

• 832112-59-1 1,2-dihydro-[1,2,4,5]tetrazine-3,6-dicarboxylic acid dihydrazide 
• 10308-83-5 N,N'-diamino-guanidine; nitrate 
• 35600-34-1 S-methylisothiosemicarbazide hydriodide 
• 44387-06-6 methyl hydrazinecarbimidothioate 
• 7697-37-2 nitric acid 
• 139047-73-7 6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 
• 79-19-6 thiosemicarbazide 
• 133488-87-6 3,6-diamino-1,2-dihydro-1,2,4,5-tetrazine monohydrochloride 
• 30169-25-6 3,6-bis-(3,5-dimethyl-pyrazol-1-yl)-1,2,4,5-tetrazine 

Downstream Products

• 153757-93-8 3,6-diamino-1,2,4,5-tetrazine 1,4-dioxide 
• 5940-53-4 3,6-dihydrazinyl-1,2,4,5-tetrazine 
• 942-60-9 5-phenyl-1,2,4-triazin-3-amine 

Relevant articles and documents

Synthesis of monosubstituted 1,2,4,5-tetrazines –3-amino-1,2,4,5-tetrazines

The substitution of pyrazolyl moiety in 3-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine with N-nucleophiles provided a series of highnitrogen tetrazine derivatives, including 2-nitro-1-(1,2,4,5-tetrazin-3-yl)guanidine, N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine, N-(1,2,4,5-tetrazin-3-yl)-1,2,4,5-tetrazin-3-amine, N,N'-di(1,2,4,5-tetrazin-3-yl)-1,2,4,5-tetrazine-3,6-diamine, N-(1,2,4,5-tetrazin-3-yl)- [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-6-amine, and tritetrazinylamine. The thermal stability of these new compounds was evaluated by differential scanning calorimetry and their energetic characteristics were calculated.

The 'inverse electron-demand' Diels-Alder reaction in polymer synthesis. Part 4.1 the preparation and crystal structures of some bis(1,2,4,5-tetrazines)

Reaction of 3,6-bis(3,5-dimethylpyrazolyl)-1,2,4,5-tetrazine with mono- and di-amines gives rise to nucleophilic substitution of one or both of the pyrazolyl substituents, and reaction with diamines under appropriate conditions can lead to bis(3-amino-1,2

COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET

The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a payload to a ligand bound to a biological target.

HETEROARYL DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS

The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.